Influenza Patent Grants with Claims to Amino Acid Sequences

Most of the patents in the table below claim peptides, ranging from about 9 amino acids to about 25 amino acids long. Most of the claims reciting full-length or near full-length proteins are drawn to equine influenza virus proteins. One patent (US 6337181) is drawn to a method for determining which HA variants are advantageous to the virus by an alignment and comparison of sequences. Although not directly claiming HA and NA sequences, US 7037707 recites a method for producing a reassortant virus in which the origin of the six segments encoding internal proteins is specified and the origin of sequences encoding HA and NA are unspecified. As such, the HA and NA could derive any other virus, including from H5N1 virus. It is not an all-encompassing claim however, because of the limitation on the origin of the other sequences.

Peptides in the claims are intended for a variety of purposes. Some recite peptides for use in vaccines comprising peptides (e.g., US 674032), while others recite peptides as part of a fusion protein, such as linked to env protein of HIV (e.g., US 6451322), or peptides that are associated with MHC molecules (US 5976551).

The patents in this table were found by either a blast-p search or a tblastn search. Except where noted, sequences have at least 95% identity to an influenza protein or a translated genome sequence. Most patents were found by both search methods; those found only in a tblastn search are noted. Claims of patents meeting the criteria were further screened to exclude those that recited an influenza sequence as a minor component of a product and those that recited method claims that were directed to fields other than influenza.

Of the 20 patent grants shown below, 9 are assigned to corporations and 11 are assigned to non-profit organizations.

Patent No.	Assignee	Title	Segment(s)	SEQ ID NO	Notes	Other Jurisdictions with Family Members
6342228	Aventis Pasteur Limited	Diagnostic kits comprising genetically engineered human immunodeficiency virus-like particles containing heterologous antigenic markers	A-Seg4	2, 3, 4	Diagnostic kit for detecting abs reactive with HIV-like particle having a non-retroviral, non-mammalian anchor sequence, peptides 2, 3, or 4. only found in tblast-n	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan, Mexico
6451322	Aventis Pasteur Limited	Retrovirus like particles made non infectious by a plurality of mutations	A-Seg4	2, 4	Non-infectious HIV-like particle w antigenic anchor sequence. only found in tblast-n	Australia
6923970	Sanofi Pasteur Limited	Retrovirus-like particles made non-infectious by a plurality of mutations	A-Seg4	2, 3,	A HIV-like particle with modified gag, etc. and env with an anchor sequence peptide. only found in tblast-n; continuation of 6451322	Australia
7229625	Sanofi Pasteur Limited	Retrovirus-like particles made non-infectious by a plurality of mutations	A-Seg4	2, 3, 4	Peptides are used as anchor sequences in an artificial HIV-like particle. SEQ ID NO: 4 is 90% identical (l=20 aa) continuation of 6923970	Australia
6479464	Cobra Therapeutics Limited	Compositions and methods for highly efficient transfection	A-Seg5	1, 3	Cationic peptides used for improving transfection of nucleic acids. Peptides designed to have many basic residues.	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan, United Kingdom, Portugal
6291157	Connaught Laboratories Limited, Toronto	Antigenically-marked non-infectious retrovirus-like particles	A-Seg4	2, 3, 4	Methods for detecting abs to anchor peptide using an HIV-like particle comprising a gag, pol, and env having an anchor sequence peptide (2, 3, or 4). only found in tblast-n	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan, Mexico
5976551	Institut Pasteur and Institut Nationale de la Sante et de la Recherche Medicale	Altered major histocompatibility complex (MHC) determinant and method of using the determinant	Seg 4, 7 A-Seg5	19, 20, 22, 23, 24	Claim 8: Compositions of peptides associated with altered MHC class II polypeptides. For eliciting immune responses to peptides.	-
6245532	Protein Sciences Corporation	Method for producing influenza hemagglutinin multivalent vaccines	A-Seg4	7, 9	Claim 1: Amino acids 1-18 of SEQ IDs 7 or 9, which is signal peptide, linked to a heterologous aa sequence.	Austria, Australia, Brazil, Canada, China, Czech Republic, Germany, Denmark, Europe. Spain, Finland, Hong Kong, Iceland, Hungary, Japan, Lithuania, Norway, New Zealand, Portugal, Slovakia
5861475	Research Corporation Technologies, Inc.	Compositions and methods for the inhibition of phagocytes	Seg5 - nucleoprotein (NP)	1, 2, 16	Peptides of defined sequence. For inhibiting phagocyte activation. To extent that they are identical over length of peptide to NP, then are important. 1 and 2 and 16 are 100%; all are short about 10-11 aa peptide	Australia
5616327	SRI International; New York Medical College	M-protein peptides of influenza virus as antiviral agents	Seg7 - matrix	1	Claim 1: Peptide from M protein that inhibits influenza transcription.	Canada, Germany, Europe, Japan
7037707	St. Jude Children's Research Hospital	Method for generating influenza viruses and vaccines	A-Seg8	3, 4, 5, 6	Cl 1 and 15: Method for producing reassortant influenza virus by transfecting host cells wwith expression plasmids containing PB2 PB1 PA NP M genes from A/PuertoRico/8/34 virus and NS sequence encoding NS1 (ID 3 or 5) and NS2 (ID 4 or 6) and HA and NA from other virus.	World
6337181	Inventors: Jeffrey Joseph Stewart et al.	Method of specifying vaccine components for viral quasispecies	A-Seg4	1, 7, 8, 9	ID nos 1, 7, 8, and 9 are variants of H3 HA and claims are drawn to method for determining which variants are advantageous to virus by alignments and analysis Also methods for screening for neutralizing mAbs. (variants are 90-92% identical)	-
6720409	Takara Shuzo Co., Ltd.	Anti-human influenza virus antibody	A-Seg4	50, 58	Claim 3: Gene sequence that encodes HA polypeptide that has antigenicity of stem region but lacks globular head region. For raising antibodies and for a vaccine.	Canada, Germany, Europe, Japan
6579528	The University of Pittsburgh	Cold-adapted equine influenza viruses	A-Seg7; B-Seg7	5	Nucleic acid encoding SEQ ID 5 - M protein of equine influenza virus.	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
6685946	The University of Pittsburgh	Cold-adapted equine influenza viruses	A-Seg2; B-Seg1	69, 92, 107	Claim 1: Nucleic acid that encodes protein (SEQ ID 69 or 92 or107), which is an equine influenza PB1, PB1-N or PB1-C protein.	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
6824784	The University of Pittsburgh	Cold-adapted equine influenza viruses	A-Seg4	11	Claim 2: Nucleic acid molecule encoding SEQ ID 11, which is HA. only found in tblast-n search	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
7074414	The University of Pittsburgh	Cold-adapted equine influenza viruses	A-Seg1; B-Seg2	28	Claim 1: Equine influenza PB2 protein from H3N8 (continuation filed)	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
7201909	The University of Pittsburgh	Cold-adapted equine influenza viruses	A-Seg4	1	Equine flu protein HA continuation of 6824784	Austria, Australia, Canada, Germany, Denmark, Europe, Spain, Japan
6740325	Yeda Research and Development Co. Ltd	Peptide-based vaccine for influenza	A-Seg4 A-Seg5	2, 4, 5	Claim 1: synthetic peptide flu vaccine, comprising at least 4 epitopes: HA peptide reactive with B cells; HA peptide (SEQ ID No. 2) reactive with T cells; 2 NP peptides (~15 aa of SEQ IDs 4 and 5) reactive with CTLs	Australia, Brazil, Canada, Europe, Israel, Japan, New Zealand
7192595	Yeda Research and Development Co. Ltd.	Peptide-based vaccine for influenza	A-Seg4	1, 2, 3, 11	Claim 1: synthetic peptide flu vaccine, comprising at least 4 epitopes: HA peptide reactive with B cells (17 aa of SEQ ID 1); peptide reactive with T cells (~15 aa from SEQ ID 2 or 3 or 11); 2 peptides (~15 aa of SEQ IDs 10, 12, 13) reactive with CTLs	Australia, Brazil, Canada, Europe, Israel, Japan, New Zealand

The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.

Comments (0)

Previous Next

CAMBIA Login